Elixinol Global Stock Revenue
| ELLXF Stock | USD 0.01 0.01 205.56% |
Fundamental analysis of Elixinol Global allows traders to better anticipate movements in Elixinol Global's stock price by examining its financial health and performance throughout various phases of its business cycle.
Elixinol |
Elixinol Global Company Revenue Analysis
Elixinol Global's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Elixinol Global Revenue | 14.13 M |
Most of Elixinol Global's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elixinol Global is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, Elixinol Global reported 14.13 M of revenue. This is 99.81% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The revenue for all United States stocks is 99.85% higher than that of the company.
Elixinol Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elixinol Global's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Elixinol Global could also be used in its relative valuation, which is a method of valuing Elixinol Global by comparing valuation metrics of similar companies.Elixinol Global is currently under evaluation in revenue category among its peers.
Elixinol Fundamentals
| Return On Equity | -0.71 | |||
| Return On Asset | -0.33 | |||
| Profit Margin | (1.72) % | |||
| Operating Margin | (1.63) % | |||
| Current Valuation | 2.06 M | |||
| Shares Outstanding | 316.27 M | |||
| Shares Owned By Insiders | 15.67 % | |||
| Shares Owned By Institutions | 4.83 % | |||
| Price To Book | 0.72 X | |||
| Price To Sales | 0.59 X | |||
| Revenue | 14.13 M | |||
| Gross Profit | 4.9 M | |||
| EBITDA | (24.15 M) | |||
| Net Income | (17.02 M) | |||
| Cash And Equivalents | 6.93 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 250 K | |||
| Debt To Equity | 0.17 % | |||
| Current Ratio | 3.58 X | |||
| Book Value Per Share | 0.04 X | |||
| Cash Flow From Operations | (14.07 M) | |||
| Earnings Per Share | (0.04) X | |||
| Number Of Employees | 17 | |||
| Beta | 1.71 | |||
| Market Capitalization | 6.5 M | |||
| Total Asset | 25.33 M | |||
| Z Score | 15.0 | |||
| Net Asset | 25.33 M |
About Elixinol Global Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elixinol Global's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elixinol Global using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elixinol Global based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| VOO | Vanguard SP 500 | |
| XLK | Technology Select Sector | |
| XLV | Health Care Select | |
| QQQ | Invesco QQQ Trust | |
| XLC | Communication Services Select |
Other Information on Investing in Elixinol Pink Sheet
Elixinol Global financial ratios help investors to determine whether Elixinol Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Elixinol with respect to the benefits of owning Elixinol Global security.